The document discusses respiratory pharmacology and diseases. It covers the autonomic innervation of the airways, commonly encountered respiratory diseases like asthma, COPD and allergic rhinitis. It then focuses on asthma, describing its clinical features, pathophysiology, risk factors, and treatment approaches including bronchodilators, corticosteroids, mast cell stabilizers and leukotriene antagonists. Treatment for an acute severe asthma attack is also outlined. Chronic obstructive pulmonary disease is briefly introduced.

1. RESPIRATORY
PHARMACOLOGY
1

2. 10/26/2022 2
The autonomic innervation of human airways
•Parasympathetic innervations: innervates bronchial
smooth muscle. Causes contraction of bronchial smooth
muscle, and increase mucosal secretion. (M3 receptors)
•Sympathetic innervations: innervate tracheobronchial
blood vessels and glands but not airway smooth muscle,
and increase mucociliary clearance.
Inhibitory Non-noradrenergic non-cholinergic
nerves (NANC ): releasing vasoactive intestinal peptide
and nitric oxide, are important neural bronchodilator.
Excitatory NANC nerves cause neuroinflammation by
releasing tachykinins: substance P and neurokinin A.

3. Commonly encountered respiratory diseases
 Asthma
 Chronic obstructive pulmonary disease (COPD)
 Allergic rhinitis
 Cough
• Adequately controlled through a combined approach of
appropriate lifestyle changes and medication mgt

4. Asthma
Clinical features of asthma
 Asthma is defined as recurrent reversible airway
obstruction, with attacks of wheeze, shortness of breath and
often nocturnal cough. Severe attacks cause hypoxaemia
and are life-threatening.
 Essential features include:
– airways inflammation, which causes
– bronchial hyper-responsiveness, which in turn results in
– recurrent reversible airway obstruction. 4

5. • Narrowing of the airway in acute asthmatic attacks results
from
 Contraction of the airway smooth muscle
 Thickening of the bronchial mucosa
» Edema
» Lymphocyte and eosinophils infiltration
» Hyperplasia of secretory, vascular, and smooth
muscle cells
Pathological features
» Lymphocytic, eosinophilic inflam. of the bronchial
mucosa
» Deposition of collagen beneath the epithelium’s lamina
reticularis 5

6. 6

7. Risk Factors
• Bronchospasm can be provoked by non-allergenic stimuli
–Genetic
–Exercise
–Cold air
–Sulfur dioxide
–Drug induced asthma
–Rapid respiratory maneuvers, or
–allergen ( proteins from house dust mites,
cockroach, cat dander, molds, and pollen)
• Drugs can be delivered
– Topically to the nasal mucosa
– Inhaled into the lungs, or
– Given orally or parenterally for systemic 7

8. Treatment of Asthma
• Antiasthmatic drugs include:
bronchodilators and anti-inflammatory agents
1. Bronchodilators
a) 2-adrenoceptor agonists
b)Methylxanthines
c) Muscarinic antagonists
2. Corticosteroids
3. Mast cell stabilizers
4. Leukotriene modifiers
 Zileuton
 Zafirlukast, Montelukast
5. Anti- IgE therapy , Omalizumab 8

9. Control of bronchial smooth muscle contraction
10/26/2022 9
Bronchodilation is promoted by cAMP. Intracellular levels of cAMP can be increased by
-adrenoceptor agonists, which increase the rate of its synthesis by adenylyl cyclase
(AC); or by phosphodiesterase (PDE) inhibitors such as theophylline, which slow the
rate of its degradation. Bronchoconstriction can be inhibited by muscarinic antagonists
and possibly by adenosine antagonists.

10. Treatment of asthma
Bronchodilators
Beta2 adrenoreceptor agonists
– MOA
• Activation of B2 – Receptors  ↑ cAMP 
bronchial smooth muscle relaxation
• Inhibits the function of numerous inflammatory
cells
»Mast cells, basophils, eosinophils,
neutrophils, and lymphocytes
10

11. Treatment of asthma
1. Short acting B2 agonists
• Salbutamol, Terbutaline, Pirbuterol, Metaproterenol
• Onset of action within 5 minutes after inhalation
• Duration of action spans 2-6 hrs
• Available in Metered-dose inhalers and nebulized
aerosols
• Rapid symptomatic relief of dyspnea associated with
asthmatic attack bronchoconstriction
• Salbutamol, Terbutaline, and Metaproterenol are also
11

12. Treatment of asthma
2. Long- acting B2- agonists
 Salmeterol & Formoterol
• Long duration of action ( > 12 hours)
• Used for maintenance Rx of asthma
» Taken Regularly
 Agent of choice for nocturnal asthma
• To significantly inhibit the inflammation a
combination with steroids is recommended
 Salmeterol and fluticasone
 Formoterol and budesonide
12

13. Treatment of asthma
Adverse Effects of B2- agonists
• Inhalational use → adverse effects are uncommon
• Oral & parentral use
– if dosage is excessive 
» angina pectoris
» tachyarrhythmias
» Tremor
13

14. Treatment of asthma
Non B2 specific bronchodilators
 Epinephrine ( Adrenaline)
• Effective and rapidly acting bronchodilator (sc or
inhalation)
• Peak bronchodilation is achieved 15 minutes after
inhalation and lasts 60-90 minutes
• Its use in asthma has been displaced by selective agents
» Reserved to treat acute vasodilation, shock
and bronchospasm of anaphylaxis
14

15. Treatment of asthma
Non B2 specific bronchodilators…
 Ephedrine
• Mixed-acting sympathomimetic drug
• Ephedrine is now used infrequently to treat asthma
• As compared to epinephrine
 Ephedrine has a longer duration, oral activity,
more pronounced central effect, much lower
potency
 Isoproterenol
• Very potent bronchodilator; when inhaled, maximal
effect with in 5 minutes, has 60-90 minute duration
of action 15

16. Treatment of asthma
Methylxanthines
Used only when other drugs such as beta 2 specific
agents are ineffective.
 Theophylline, caffeine,theobromine
Theophylline
• MOA
a) By inhibiting PDE  ↑cAMP 
bronchodilation
o↓ Release of inflammatory mediators
b) Inhibition of cell surface receptors for
adenosine
16

17. Treatment of asthma
• Pharmacological Effects
– Prominent actions are:
• Bronchodilator
• CNS stimulation
• Other actions include
–Cardiac stimulation (↑ catecholamine
release)
–Vasodilation (except cerebral blood vessels)
–GIT - gastric acid & digestive enzymes
–Diuresis
17

18. Treatment of asthma
• Therapeutic uses
 Relieve airway obstruction in acute asthmatic attack
 Add-on therapy to inhaled corticosteroids and long-
acting β2 agonists (long term controller)
 Appropriate for noctural asthma (b/c of prolonged
effects)
 IV theophylline (Aminophylline) is employed in
emergencies.
• Toxicity
• has a narrow therapeutic window: cardiac dysrhythmia,
seizures and gastrointestinal disturbances
 Most likely at plasma levels > 40mg/L
» Ventricular arrhythmia
» Convulsions
» Headache, nausea, vomiting 18

19. Treatment of asthma
• Other preparations:
 Aminophylline, LD 5.7 mg/kg, MD 5mg/kg
(Theophylline +Ethylene diamine)
– More water soluble than theophylline
 Theophendrine (Theophylline + Ephedrine), (11mg
+ 120mg) P.O. BID OR TID
• Drug Interactions
 Drugs that ↓ theophylline levels
• Phenobarbitone Phenytoin,
carbamazepine,rifampicin
 Drugs that ↑ theophylline levels
19

20. Anticholinergic Agents
• Ipratropium bromide, tiotropium
• Available for inhalational administration
• M3 receptor antagonism is responsible for the
bronchodilation
• Slow and low intensity bronchodilation
• Combined use with β2-agonist provides better
outcomes
• Tiotropium has long duration of action (24 hrs duration)
Improve functional capacity of pts with COPD
=/Most common side effect is dry mouth 20

21. Treatment of asthma
Corticosteroids
• The most effective drugs available for long term control
• MoA: Act primarily by suppressing:-
» Synthesis & release of inflammatory mediators
» Infiltration & activation of inflammatory cells
» Edema of the air way mucosa (2o to vascular
permeability)
» Reduces bronchial hyperreactivity
 ↑number of B2 adrenoceptors ↑ responsiveness to
agonist
21

22. Treatment of asthma
Rout of therapy:
1) Inhalational therapy
• Considered 1st line therapy
• Low risk
• Should be used with B2- agonists
2) Oral therapy
• For pts with severe asthma
• Duration should be as short as possible
(toxicity)
3)Injectable
Adverse Effects:
a) Inhalational
• Generally devoid of serious toxicity
 Oropharyngeal candidiasis 22

23. Treatment of asthma
b) Oral
• Used for > 15 days can be hazardous
– Osteoporosis
– Hyperglycemia
– PUD
– Adrenal suppression
– Suppression of growth in children
23

24. Treatment of asthma
Preparations of corticosteroids
1. Oral
 Prednisolone, beclomethasone
2. Inhalational
 Beclomethasone, Dexamethasone,
Triamcinolone, budesonide, fluticasone,
momentasone, flunisolide
3. Injectable
 Hydrocortisone, methylprednisolone,
24

25. Severe acute asthma (status
Asthmaticus)
• Medical emergency requiring hospitalization
• Treatment includes oxygen
• Inhalation of salbutamol given by nebulizer,
and intravenous hydrocortisone followed by a
course of oral prednisolone
• Additional measures occasionally used include
nebulised ipratropium, intravenous
salbutamol or aminophylline, and antibiotics
(if bacterial infection is present)
10/26/2022 25

26. Treatment of asthma
Mast cell stabilizers
• Cromolyn Sodium, nedocromil
 Very safe & effective for prophylaxis of asthma
 Administered by inhalation
 MoA
 Acts by stabilizing the cytoplasmic membrane ↓
release of mediators
 Inhibits activation of other inflammatory cells
 Chronic administration ↓ Inflammation &
bronchial hyperreactivity
26

27. Treatment of asthma
• Cromolyn Sodium, nedocromil
• Therapeutic uses:
» Asthma (long term controller)
» Exercise, unavoidable allergen exposure
induced asthma (prophylaxis)
» Allergic rhinitis
• Adverse effects
Throat irritation, cough and mouth dryness, and
rarely chest tightness and wheezing
27

28. 10/26/2022 28
Leukotriene Antagonists
Leukotrienes are mediators released from mast cells
upon contact with allergens.
Contribute powerfully to both inflammation and
bronchoconstriction
Can either block the synthesis of leukotrienes or
block their receptors.
Zileuton (Zyflo) is the prototype of those that block
the synthesis of leukotrienes
Zafirlukast (Accolate) is the prototype of those that
block their receptors

29. STG asthma
• First line
• Salbutamol Salbutamol, 200 micrograms, 2 puffs
/5min
• Alternatives
• Aminophylline, 5mg/kg by slow I.V. push over 5
minutes, I.V. infusion at 0.6 mg/kg/hr
• OR
• Adrenaline, 1:1000, 0.5ml sc. Repeat after ½ to 1
hour if patient doesn’t respond.
• If seviere, Aminophylline + Hydrocortisone , 200
mg IV stat OR Prednisolone, 40-60 mg P.O 5-7 ds
10/26/2022 29

30. 10/26/2022 30
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (CO
Cigarette smoking is the main cause
Clinical features. morning cough during the winter,
often initiated by a cold. There is progressive
breathlessness, airflow obstruction
Pathogenesis. There is small airways fibrosis, resulting
in obstruction, and/or destruction of alveoli and of elastin
fibres in the lung parenchyma. The latter features are
hallmarks of emphysema,

31. 10/26/2022 31
Principles of treatment.
•Stopping smoking,
•Short- and long-acting inhaled
bronchodilators (ipratropium, salbutamol )
•Long-term oxygen therapy
•Broad-spectrum antibiotics (e.g.
cefuroxime)
•glucocorticoid (intravenous hydrocortisone
or oral prednisolone)

32. 10/26/2022 32
Allergic rhinitis
Rhinitis is an inflammation of the mucous membranes of
the nose and is characterized by
sneezing
itchy nose/eyes,
watery rhinorrhea, and
nasal congestion
Combinations of
oral antihistamines(loratadine,and fexofenadine,
Cetrizine, 10mg BID, Dexchlorpheniramine
maleate,: 6mg P.O. BID), Chlorpheniramine 4mg
bid with
decongestants(Xylometazoline, 2 - 3 drops).
Corticosteroids (Beclomethasone) and Cromolyn can

33. DRUGS FOR COUGH

34. What is cough ?
 It’s a protective reflex – for expulsion of
respiratory secretions and foreign particles
from air passages
 Respiratory secretions !
 Stimulation of mechano or chemoreceptor –
throat, respiratory passages and stretch
receptors in the lungs
 Afferent fibres in vagus & sympathetic -
impulses to cough center – medulla

35. Cough – Types and Merits
 Non-productive (Dry Cough) and Productive
 Nonproductive ones need suppression –
cerebral hypoxia, rupture of bullas and fracture
ribs etc.
 Productive – needs to clear airway
 May be harmful if suppressed !
 Amount of product Vs effort of coughing
 Most of the time, coughing is beneficial
 Removes excessive secretions
 Removes potentially harmful foreign substances
 In some situations, coughing can be harmful, such as after
hernia repair surgery

36. Cough Etiology
1. Upper/Lower Respiratory Tract Infection
2. Postnasal drip due to sinusitis, rhinitis
3. Smoking/Chronic Bronchitis
4. Pulmonary Tuberculosis
5. Asthmatic cough
6. Gastrointestinal reflux
7. Drugs – Captopril and Iodides ……

37. Cough – Drugs (Nonspecific)
1. PHARYNGEAL DEMULCENTS: Lozenges, cough drops,
linctuses glycerine and liquorice
2. EXPECTORANTS: (MUCOKINETICS – secretion
enhances):
a) Secretion Enhancers: Sodium and Potassium citrate, KI,
Guaiphenesin (Glyceryl guaicolate), Vasaka, Ammonium
chloride
b) Mucolytics: Bromhexine, Ambroxol, Acetylcysteine,
Carbocysteine
3. CENTRAL COUGH SUPPRESSANTS:
a) Opioids: Codeine, Pholcodeine
b) Nonopioids: Noscapine, Dextromethorphan
c) Antihistamines: Chlorpheniramine maleate,
Diphenhydramine,promethazine
4. ADJUVANT: Salbutamol, Terbutaline

38. Drugs of Cough – Demulcents and
Expectorants
Demulcents
 Soothing effect and symptomatic relief – reduce
afferent impulses - act by increasing flow of
saliva
Expectorants (Mucokinetics)
1. Increase Bronchial Secretion – Na and K
citrate
2. Irritation of Bronchial mucosa – Iodides
3. Enhance Bronchial secretions (and
mucociliary functions) – Guaiphenesin,
Vasaka
4. Ammonium salts – nauseating, reflex
stimulation of bronchial secretion

39.  Bromhexine: Derivative of Adhatoda vasica
(Vasaka) – increases bronchial secretion
Depolymerises mucopolysaccharides in bronchial
secretions – directly or by liberating lysosomal enzyme
Fibres of sputum breaks down
Useful in mucus plug
 Ambroxol: Similar to Bromhexine
 Acetylcysteine: Breaks sulfide bond in
mucopolysaccharides of bronchial secretions –
Respiratory tract administration
 Carbocysteine: Similar to acetylcysteine –
administered orally
Actions of Drugs of Cough – Mucolytics

40. 40
Antitussives
 Act in the brain stem, depressing cough center
 Used only for dry (unproductive) cough
Can cause harmful sputum thickening and retention
 Should not be used for the cough associated with asthma
 Drugs:
 Dextrometorphan, Codeine, hydrocodone, hydromorphone
 Cough mixtures may also contain
Antihistamines: chlorpheniramine, diphenhydramine
Decongestants: pseudoephedrine, phenylephrine
Wednesday, October 26,
2022

41. Antitussive - Codeine
Opioid – opium alkaloid – methyl morphine
 Partly converts to Morphine
Less potent than Morphine and degree of
analgesia is equivalent to Aspirin (60 mg)
But, more selective for cough centers and
action lasts for 6 Hours
Blocked by Naloxone
Low abuse liability
Drawbacks: constipation, respiratory
depression and drowsiness (Higher doses)
PHOLCODEINE: No analgesia or addicting
property – longer acting

42. Cough Drugs - Nonopioids
 Noscapine: Opium alakaloid
 Depresses cough, but no analgesic, narcotic or
dependence liability
 Equipotent with codeine – spasmodic cough
 Histamine release – no in asthma
 Dextromethorphan:
 Synthetic – d-isomer (antitussive) and l-isomer (analgesic)
 Effective as codeine but no addicting and constipating effect
– No impairment of mucocilliary function
 But, dissociative effect – recreational drug?
 In Combination – Paracetamol (acetaminophen)

43. Cough Drugs
 Antihistamine:
 Chlorpheniramine, Diphenhydramine and
Promethazine
 MOA: Sedative and anticholinergic
 Useful in allergic cough
 Bronchodilators:
 Bronchospasm can induce cough and constriction
 Hyperactivity of Bronchial smooth muscles
 Bronchodilators – relieves cough and improves
clearance during cough

44. Wednesday, October 26,
2022
44